Trial Profile
Phase I Study of Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Capecitabine
- Indications Adenocarcinoma; Advanced breast cancer; Brain metastases; HER2 positive breast cancer
- Focus Adverse reactions
- 25 Jan 2021 Status changed from active, no longer recruiting to completed.
- 03 Feb 2020 Planned End Date changed from 1 Jan 2020 to 1 Jan 2021.
- 03 Feb 2020 Planned primary completion date changed from 1 Jan 2020 to 1 Jan 2021.